Importantly, our data showed that treatment with BPIs effectively suppressed NF-κB signalling in ACB-DLBCL cells and repressed the growth of ACB-DLBCL cells but not normal cells, implicating BCL10 targeting as a viable strategy for ACB-DLBCL therapy. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.